newsfilter
← Latest News
GlobeNewswire·

Cara Therapeutics Reports Second Quarter 2023 Financial Results

– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in